Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind,...

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• SYHX2011 is a novel albumin-bound paclitaxel formulation utilizing mannitol and sucrose instead of most non-particulate human albumin.
• Albumin-bound paclitaxel formulations are crucial in treating advanced breast cancer.

Purpose of the Study:

• To compare the efficacy and safety of SYHX2011 against paclitaxel for injection (albumin-bound) (PAB) in patients with unresectable locally advanced or metastatic breast cancer.
• To assess SYHX2011's noninferiority and potential superiority in objective response rate (ORR).

Main Methods:

• A multicenter, randomized, double-blind, phase III trial involving 459 patients with advanced breast cancer.
• Patients received either SYHX2011 (260 mg/m²) or PAB (260 mg/m²) intravenously every 3 weeks.
• Primary endpoint was objective response rate assessed by an independent review committee, with stratification based on prior taxane use and chemotherapy history.

Main Results:

• SYHX2011 demonstrated a significantly higher confirmed objective response rate (35.8%) compared to PAB (25.8%), confirming noninferiority and superiority (rate ratio 1.38, 95% CI 1.04-1.84).
• SYHX2011 showed a markedly lower incidence of rash during the first 2 cycles (13.6% vs. 34.3%) and overall (16.2% vs. 42.6%).
• Treatment-related adverse events were comparable, though SYHX2011 had a faster reconstitution time (2.0 min vs. 11.0 min).

Conclusions:

• SYHX2011 offers superior therapeutic benefits and a significantly reduced incidence of rash compared to PAB in advanced breast cancer.
• The novel formulation provides enhanced clinical convenience and presents a safer, more effective treatment alternative for patients.
• The study supports SYHX2011 as a promising new option for advanced breast cancer management.